相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Robert Ratner et al.
CARDIOVASCULAR DIABETOLOGY (2011)
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
Kathleen J. Griffioen et al.
CARDIOVASCULAR RESEARCH (2011)
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
R. Keith Campbell
CLINICAL THERAPEUTICS (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
J. Z. Dong et al.
DIABETES OBESITY & METABOLISM (2011)
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
M. C. Bunck et al.
DIABETES OBESITY & METABOLISM (2011)
DURABILITY OF EFFECTS OF EXENATIDE TREATMENT ON GLYCEMIC CONTROL, BODY WEIGHT, SYSTOLIC BLOOD PRESSURE, C-REACTIVE PROTEIN, AND TRIGLYCERIDE CONCENTRATIONS
Ajay Varanasi et al.
ENDOCRINE PRACTICE (2011)
A thorough QT study to evaluate the effects of single-dose exenatide 10 μg on cardiac repolarization in healthy subjects
H. Linnebjerg et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
Vanita R. Aroda et al.
POSTGRADUATE MEDICINE (2011)
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1
Renato O. Crajoinas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Ted Okerson et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Anne Gill et al.
CARDIOVASCULAR DIABETOLOGY (2010)
One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
M. Buysschaert et al.
DIABETES & METABOLISM (2010)
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Daniel J. Drucker et al.
DIABETES CARE (2010)
Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
Juraj Koska et al.
DIABETES CARE (2010)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study
R. Ratner et al.
DIABETIC MEDICINE (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
Monika Malm-Erjefalt et al.
DRUG METABOLISM AND DISPOSITION (2010)
Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
Kiwon Ban et al.
ENDOCRINOLOGY (2010)
Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
B. Gallwitz et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Early clinical studies with liraglutide
W. E. Schmidt
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
Lisbeth V. Jacobsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
Sean D. Sullivan et al.
CARDIOVASCULAR DIABETOLOGY (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
C. Kapitza et al.
DIABETIC MEDICINE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
The target cell response to cytokines governs the autoreactive T cell repertoire in the pancreas of NOD mice
M. Hultcrantz et al.
DIABETOLOGIA (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
Dhruba J. Chatterjee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone
Robert F. Kushner et al.
OBESITY (2009)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel et al.
LANCET (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Joshua A. Ray et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk
Gabriel I. Uwaifo et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
L Simonsen et al.
DIABETOLOGIA (2006)
An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide
Birgitte Damholt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
MN Feinglos et al.
DIABETIC MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
H Harder et al.
DIABETES CARE (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial
S Madsbad et al.
DIABETES CARE (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
P Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
B Elbrond et al.
DIABETES CARE (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)